CD38 and prostate cancer: Those trials combined respectively the anti-CD38 antibody isatuximab with an anti-PD-L1 antibody (atezolizumab) in immune naive solid tumors or following targeting CD38 with isatuximab and PD-1 with cemiplimab in immune naive patients with metastatic castration-resistant prostate cancer cases or in non-small cell lung cancer (NSCLC) cases that progressed on anti-PD-1/PD-L1-combined therapy31,32.